

CanCertain® Test Report

No.	Condition	conc.1	conc.2	conc.3	conc.4
1	Niv	0.0188	2.7240	1.09178	1.9965
2	Atz	1.3442	0.8217	0.9501	1.6594
3	Doc	1.6829	-0.1446	0.9099	-0.2489
4	Epi	0.9690	0.3774	0.4765	-0.1445
5	Vin	0.2205	1.4371	0.5106	0.3747
6	GM	-0.2244	1.1069	0.5515	0.6946
7	Pac	-0.2026	0.0841	0.9143	0
8	PMT	0.4143	1.5455	-0.3551	0.4902
9	GF	0.3325	0.7578	0.2432	-0.1362
10	Pal	-0.0983	0.2469	0.2833	-0.0667

Based on Drug Response Scores following interpretation is made:		
1	Nivolumab	R
2	Atezolizumab	R
3	Docetaxel	S++
4	Epirubicin	S+
5	Vinorelbine	R
6	Gemcitabine	R
7	Paclitaxel	S+
8	Pemetrexed	R
9	Gefitinib	S+
10	Palbociclib	S++

Under laboratory conditions, both immunotherapy drugs (Atezolizumab and Nivolumab) do not show any effectiveness. Epirubicin, Paclitaxel and Gefitinib are Mildly effective (+). Docetaxel and Palbociclib are very effective (S++). It is recommended to repeat CTC Count after 3 cycles of Chemotherapy.

DISCLAIMER: CanCertain should not be used as the sole input for the purposes of diagnosis, prognosis, or as the primary basis for making therapeutic decisions. CanCertain should be used by an experienced physician in conjunction with other recognized laboratory and diagnostic procedures, in accordance with current literature and practice guidelines. An individual patient's condition and medical history should always be considered when making any treatment decisions, and the experience and clinical judgment of the treating physician should ultimately determine which treatment is selected. CanCertain Test has been developed and its performance characteristics determined in laboratory facility of Clyz Labs Limited, UK. It has not been submitted to FDA or any other regulatory body; and such submission is currently not required. No liability is implied or expressed. Clyz Labs Limited is an award winning early stage clinical biotechnology company in UK.



Dr Himanshu Kataria
CEO
Clyz Labs Limited
UK



Ms Meghan Harrison
Laboratory Scientist
Clyz Labs Limited
UK

LIFE SCIENCES INNOVATOR

